Headache and Migraine

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 10, 2021.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Deena Kuruvilla, MD.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive team.

The assistant professor of neurology at Harvard Medical School provided insight on how to improve care for posttraumatic headache, as well as limitations and benefits to nerve block surgeries.

The assistant professor of pediatrics and neurology at the University of Colorado School of Medicine discussed the importance of headache research in gender minorities.

Here's what is coming soon to NeurologyLive.

Discussing the key takeaways for clinicians when it comes to treating this patient population, the assistant professor of pediatrics and neurology at the University of Colorado School of Medicine emphasized the need to improve communication.

Neurology News Network for the week ending September 4, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 3, 2021.

Impel’s agent is designed to deliver a lower dose of dihydroergotamine mesylate (DHE) compared with other nasally administered products.

The assistant professor of pediatrics and neurology at the University of Colorado School of Medicine spoke on a recent narrative review investigating headache in gender minorities.

Patients with chronic migraine were advised to reduce cannabis use to aid in reducing medication overuse headache.

Although headache infusion centers were generally open during the standard business hours, few headache infusion centers were open after hours and on weekends.

Here's what is coming soon to NeurologyLive.

Jennifer Hranilovich, MD, assistant professor of pediatrics and neurology at the University of Colorado School of Medicine, discussed a recent narrative review that evaluated research on headache in transgender and gender-diverse patients.

Neurology News Network for the week ending August 28, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 27, 2021.

For the primary end point, the 3 dose options atogepant (AbbVie) were associated with a reduction ranging from 3.9 to 4.2 days in the mean number of headache days per month for those with episodic migraine.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 20, 2021.

Trigger avoidance-only strategies don’t actually help migraine patients improve. These are the proactive behaviors that do.

Investigators identified 4 susceptible loci with large effect sizes, one of which has previously been associated with migraine.

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Here's what is coming soon to NeurologyLive.

Individuals with chronic and episodic migraine saw improvements in patient-reported outcomes such as MSQoL, EQ-5D-5L, PGIC, WPAI, and the 9-Item Patient Health Questionnaire.